Related Experiment Video
Updated: May 22, 2026
Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia
Published on: February 21, 2021
Targeting NKG2D in tumor surveillance
1The University of Tokyo, Graduate School of Pharmaceutical Sciences, Laboratory of Cancer Biology and Molecular Immunology, Bunkyo-ku, Japan. haya4416@mol.f.u-tokyo.ac.jp
Introduction:
NKG2D (natural killer group 2, member D) is expressed on the surface of all mouse and human NK cells, and subpopulation of T cells. Stimulation of NK cells through NKG2D triggers cell-mediated cytotoxicity and induces the production of cytokines. NKG2D binds to family of unique ligands with structurally similar to MHC class I, however, NKG2D ligands can be up-regulated in their expression on stressed cells including tumor cells unlike conventional MHC class I molecules. Mounting evidences clearly implicate that NKG2D recognition plays an important role in tumor immune surveillance.
Areas Covered:
While NKG2D detect for potentially dangerous cells, various inhibitory and/or escape mechanisms counteract immune surveillance system and thereby limit effective elimination of transformed tumor cells. In addition, tumors often generate an immunosuppressive microenvironment where inhibitory molecules or cytokines negatively effect the function of anti-tumor immune responses. NKG2D ligand expression can be up-regulated by transcriptional or posttranscriptional mechanisms, therefore, certain therapy targeting those regulatory mechanisms could regain the expression of NKG2D ligands on tumor cells to be detected by the host immune responses.
Expert Opinion:
Our knowledge in the precise mechanism of anti-tumor immunity is rapidly increasing. While NKG2D is known as primary cytotoxicity receptor in NK cell activation by recognizing 'induced-self' ligands on stressed cells including tumor cells, there are increasing evidences that NKG2D recognition can result in both immune activation and immune silencing. Future combined application of conventional cancer therapy and new therapy utilizing such stress-induced recognition systems will provide a novel opportunity to control malignant tumor progression of cancer disease.
Insights
Natural killer group 2, member D (NKG2D) is crucial for detecting stressed and tumor cells. Therapies targeting NKG2D mechanisms could enhance anti-tumor immunity and control cancer progression.
Area of Science:
- Immunology
- Cancer Biology
- Cellular Signaling
Background:
- Natural killer group 2, member D (NKG2D) is expressed on NK cells and T cells, mediating cytotoxicity and cytokine production.
- NKG2D ligands, structurally similar to MHC class I, are upregulated on stressed and tumor cells, playing a role in tumor immune surveillance.
- Tumors employ escape mechanisms and create immunosuppressive microenvironments that hinder anti-tumor immune responses.
Purpose of the Study:
- To explore the role of NKG2D in anti-tumor immunity.
- To investigate mechanisms of tumor immune evasion related to NKG2D.
- To identify therapeutic strategies targeting NKG2D for cancer treatment.
Main Methods:
- Review of existing literature on NKG2D function, ligand expression, and tumor immune evasion.
- Analysis of mechanisms regulating NKG2D ligand expression.
- Discussion of potential therapeutic interventions targeting NKG2D pathways.
Main Results:
- NKG2D recognition is vital for identifying stressed and transformed cells.
- Tumor cells can evade NKG2D-mediated immune surveillance through various inhibitory mechanisms.
- Upregulating NKG2D ligand expression on tumor cells can potentially restore immune detection.
Conclusions:
- NKG2D plays a dual role in anti-tumor immunity, potentially leading to both activation and silencing.
- Targeting regulatory mechanisms of NKG2D ligand expression offers a therapeutic avenue.
- Combined conventional and novel therapies utilizing NKG2D-mediated stress recognition show promise for controlling malignant tumors.
